Nachrichten zur Krystal Biotech Inc. Aktie

Quoin (QNRX) Q2 Loss Beats Estimates

Key PointsGAAP EPS of 6.28 was better than the estimated -6.82 for Q2 2025, GAAP EPS of 6.28 exceeded the…

Krystal Biotech, Inc. 2025 Q2 - Results - Earnings Call Presentation

…

Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

…

Krystal (KRYS) Q2 Profit Jumps 143%

Key PointsGAAP earnings per share of $1.29 surpassed estimates of $1.18 in Q2 2025, This figure represents a 143.4% increase…

Krystal Biotech shares jump as Q2 results exceed expectations By Investing.com

Krystal Biotech shares jump as Q2 results exceed expectations…

Krystal Biotech earnings beat by $0.07, revenue topped estimates By Investing.com

Krystal Biotech earnings beat by $0.07, revenue topped estimates…

How A 60-Year-Old Drug Developer Built A $4.4 Billion Biotech Treating ‘Butterfly Skin Disease’

Longtime drug developer Suma Krishnan was 51 when she cofounded Krystal Biotech. Now the company has one gene therapy on…

KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic…

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

Theres a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies…

Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?

Krystal Biotech (KRYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…

KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study

Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related…

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

Krystal Biotech (KRYS) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Krystal Biotech gets EU approval for Vyjuvek

…

Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Krystal Biotech, Inc. (KRYS) have performed compared to their sector so far…

Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?

Krystal Biotech (KRYS) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Heres Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?

KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about…

KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug

Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.…

Krystal Biotech Aktie: EU-Zulassung für Vyjuvek rückt näher

Kulmbach (www.aktiencheck.de) - Krystal Biotech-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Why Krystal Biotech (KRYS) Might be Well Poised for a Surge

Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid…

Krystal Biotech (KRYS) Upgraded to Buy: Heres What You Should Know

Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…

Krystal Biotech: Umsatzanstieg von 473 % durch Gentherapie für schwere Hauterkrankungen

Viele genetisch bedingte Hautkrankheiten führen zu erheblichen Einschränkungen der Lebensqualität. Im Rahmen der klassischen Pharmazie war hierbei lediglich eine symptomatische…

Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up

KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuveks launch in the United States shows strong uptake.…

Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy

…

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy…

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial…

KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat…

Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript

…

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company,…

Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On

…

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company,…

Surging Earnings Estimates Signal Upside for Krystal Biotech (KRYS) Stock

Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid…

Krystal Biotech: Positives Phase-1-Update für KB301 - Aktienanalyse

Charlotte (www.aktiencheck.de) - Krystal Biotech-Aktienanalyse von BofA Securities: Alec Stranahan, Analyst von BofA Securities, hebt in einer aktuellen Aktienanalyse sein Kursziel…

Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?

KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging…

Krystal Biotech, Inc. 2024 Q2 - Results - Earnings Call Presentation

…

Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call Transcript

…

Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates

Net product revenue of $70.3 million in 2Q and $166.2 million since launch in August 2023…

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Top Estimates

Krystal Biotech (KRYS) delivered earnings and revenue surprises of 72% and 18.66%, respectively, for the quarter ended June 2024. Do…

Krystal Biotech Q2 2024 Earnings Preview

…

Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)

…

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company,…

Krystal Biotech: Eine wahre Biotech-Perle - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Krystal Biotech-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

AKTIONÄR-Hot-Stock Krystal Biotech nicht zu bremsen: Nächstes Rekordhoch!

Krystal Biotech ist eine wahre Biotech-Perle. Am Dienstag erreichte die Aktie des amerikanischen Unternehmens eine neue Bestmarke. Inzwischen spendiert der…

AKTIONÄR-Hot-Stock Krystal Biotech nicht zu bremsen: Nächstes Rekordhoch!

Krystal Biotech ist eine wahre Biotech-Perle. Am Dienstag erreichte die Aktie des amerikanischen Unternehmens eine neue Bestmarke. Inzwischen spendiert der…

Krystal Biotech, Virtu, StepStone, Cactus, Tidewater to join S&P 600

…

Krystal Biotech wird Teil des S&P SmallCap 600 - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Krystal Biotech-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Krystal Biotech Inc.…

AKTIONÄR-Hot-Stock Krystal Biotech: Ritterschlag!

Wie auch in Deutschland findet eine regelmäßige Überprüfung großer Indizes in den USA statt. So vor Kurzem auch im Hause…

Krystal Biotech (KRYS) Gains 36% Year to Date: Heres Why

Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.…

Krystal Biotech: VYJUVEKs Blockbuster Potential In Gene Therapy For DEB

…